220805-31-2

Upstream product

• 3587-60-8 Benzyloxymethyl chloride 
• 2163-48-6 diethyl propylmalonate 
• 100-51-6 benzyl alcohol 
• 143868-89-7 3-(1-oxopentyl)-4(S)-(phenylmethyl)-2-oxazolidinone 
• 638-29-9 n-valeryl chloride 
• 220805-27-6 3-(3-benzyloxymethyl-2R-n-propylpropionyl)-4S-benzyloxazolidin-2-one 

Downstream Products

• 220805-35-6 2R-benzyloxymethylpentanoic acid diethylamide 
• 63095-51-2 (+)-(R)-4-propyl-4,5-dihydrofuran-2(3H)-one 
• 220805-49-2 3-(5S-isopropyl-4S-methoxycarbonyl-2-phenyl-4,5-dihydrooxazol-4-yl)-3S-hydroxy-2R-n-propyl-N,N-diethylpropionamide 
• 211866-70-5 [1R-[1S,4R,5S]]-1-(1-hydroxy-2-methylpropyl)-4-n-propyl-6-oxa-2-azabicyclo[3.2.0]heptane-3,7-dione 

Relevant academic research and scientific papers

Preparation method for brivaracetam intermediate

The invention discloses a preparation method for (R)-4-propyl-4,5-dihydrofuran-2-one. The preparation method comprises the following steps: subjecting a carboxylic acid compound to chiral resolution so as to obtain an R-configuration carboxylic acid compound and an S-configuration carboxylic acid compound; and separately subjecting the R-configuration carboxylic acid compound and/or the S-configuration carboxylic acid compound to a reaction so as to obtain (R)-4-propyl-4,5-dihydrofuran-2-one. According to the preparation method, a synthetic route is ingeniously designed, and the two opticallypure isomers obtained through chiral resolution of the carboxylic acid compound are separately utilized by different reaction routes, so the target compound is eventually prepared; and the method improves the utilization rate of the isomers while ensuring optical purity and eliminates the cumbersome steps of racemization and re-splitting of the other half of the isomers.

A novel and efficient synthesis of a highly active analogue of clasto-lactacystin β-lactone

Herein, we describe a new convergent synthesis of a more potent analogue of clasto-lactacystin β-lactone (2), PS-519 compound 4, which is currently in preclinical development for the treatment of ischemia-reperfusion injury in stroke and myocardial infarction. The synthetic strategy relies on building two intermediates (an oxazoline and an aldehyde) which are joined through a doubly diastereoselective aldol reaction, setting up the requisite unichiral centers in the final product (4). The facial selectivity and ultimate stereocontrol are achieved by employing a trivalent aluminum Lewis acid, Me2AlCl, in a chelation-induced reaction which yields a single aldol adduct. The efficiency of the synthetic approach has allowed for the preparation of multigram quantities of clinical grade material, which will support Phase I studies.